News | August 10, 2021
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
